Feasibility study of GGDPS inhibition for osteoporosis
Feasibility study of GGDPS inhibition for osteoporosis
批准号:
8522844
负责人:
JEFFREY D NEIGHBORS
金额:
$16.31万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2014-08-31
关键词:
Advanced DevelopmentAdvocateAffectAffinityAnabolismApoptosisBindingBiological MarkersBiological ProcessBone MatrixBone ResorptionBone necrosisBone remodelingCalciumCaringCell LineCellsCharacteristicsClinicalCultured CellsCyclophosphamideDataDetectionDevelopmentDiseaseDisease modelDrug KineticsEnzymesEuropeFeasibility StudiesFoundationsFractureFunctional disorderFundingGoalsHealth Care CostsHumanIn VitroInternationalInterventionIsopreneJapanJawKidneyLeadLibrariesMeasurementMeasuresMechanical StressMechanicsMediatingMetabolismModalityModelingNew AgentsNitrogenOsteoblastsOsteocalcinOsteoclastsOsteocytesOsteoporosisPathway interactionsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPhasePopulationPrevalenceProcessProductionProtein GeranylgeranylationPublic HealthQuality of lifeRattusRegulationRelative (related person)ResistanceSeriesSmall Business Innovation Research GrantSolutionsSupplementationTRANCE proteinTestingTherapeuticToxic effectVitamin Dbasebisphosphonatebonebone strengthbone turnovercathepsin Kclinical applicationfarnesyltranstransferasegeranylgeranyl diphosphatehydroxyl groupin vitro Modelin vitro activityin vivoin vivo Modelinhibitor/antagonistisoprenoidnovelpatient populationpharmacophorephase 1 studyphase 2 studyprogramspublic health relevanceskeletalsmall moleculesmall molecule librariesspine bone structurestandard care
中文摘要
描述(由申请人提供):这些研究的目的是确定专利香叶基香叶基二磷酸合成酶抑制剂(GGSIs)与当前标准治疗药物相比,在抑制破骨细胞介导的骨吸收方面的功效。我们已经开发了一组含有异戊二烯亚结构的专有双膦酸盐,在体外显示出高度有效和特异性的GGSI活性。这些化合物不含有羟基或氮亚结构的目前的双磷酸盐,这是临床上使用的。我们的ggsi代表了双膦酸盐发展的重大进步,因为它们针对的是相对于临床双膦酸盐的下游酶。我们认为,基于我们初步研究的力度,以及对骨质疏松症这种日益严重的公共卫生问题的额外治疗的持续需求,我们有必要进一步开发用于治疗骨质疏松症的新型GGSIs。事实上,据估计,到2025年,骨质疏松症每年将导致价值250亿美元的医疗费用。在这里,我们提出了SBIR I期研究,以证明GGSIs在骨质疏松症常用大鼠模型中的可行性。本提案中描述的可行性研究提供了一种简化的方法,可以使用体外模型从我们的文库中识别最具活性的GGSI,并将这些活性化合物转化为体内骨吸收模型。在具体目标一中,我们将使用基于细胞的模型来优先考虑基于破骨细胞吸收活性和成骨细胞凋亡抑制的化合物。然后,在具体目标二中,我们将在去卵巢的骨质疏松大鼠模型中使用最优先的化合物,并将体外数据与体内骨强度测量、机制参与的生物标志物、骨吸收的生物标志物和成骨细胞凋亡的体外标志物相关联。总之,这些目标将为我们提供一个进行或不进行更详细的IND研究的决定。
英文摘要
DESCRIPTION (provided by applicant): The goal of these studies is to determine the efficacy of proprietary geranylgeranyl diphosphate synthase inhibitors (GGSIs), for inhibition of osteoclast mediated bone resorption in comparison to current standard-of-care agents. We have developed a group of proprietary bisphosphonates containing isoprene substructures that demonstrate highly potent and specific GGSI activity in vitro. These compounds do not contain the hydroxyl group or the nitrogen substructure of the current bisphosphonates, which are used clinically. Our GGSIs represent a significant advance in bisphosphonate development in that they target a downstream enzyme relative to the clinical bisphosphonates. We feel that further development of our novel GGSIs for the treatment of osteoporosis is warranted based on the strength of our preliminary studies and the ongoing need for additional treatments for this disease which represents a significant and growing public health problem. Indeed, it is estimated that by 2025 osteoporosis will result in $25 billion worth of health costs each year. Here we propose SBIR Phase I studies to prove the feasibility of GGSIs in osteoporosis in a commonly used rat model of the disease. The feasibility studies described in this proposal provide a streamlined approach towards identification of the most active GGSI towards bone resorption from our library using in vitro models, and transition of these active compounds into an in vivo model of bone resorption. In specific aim one we will use cell based models to prioritize our compounds based on osteoclast resorption activity and inhibition of osteoblast apoptosis. Then in specific aim two we will use the highest priority compound in an ovariectomized rat model of osteoporosis and correlate the in vitro data to in vivo measurements of bone strength, biomarkers of mechanism engagement, biomarkers of bone resorption, and ex vivo markers of osteoblast apoptosis. Together these aims will provide us with a go or no-go decision for more elaborate IND enabling studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Schweinfurthins: novel treatment for breast cancer
-
批准号:7798657
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2010
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Pawhuskins: Potential Treatments for Stimulant Abuse.
-
批准号:7638987
-
项目类别:
-
资助金额:$19.81万
-
财政年份:2009
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Pawhuskins: Potential Treatments for Stimulant Abuse.
-
批准号:7842616
-
项目类别:
-
资助金额:$22.03万
-
财政年份:2009
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Improving the Distribution of Geranylgeranyl Diphosphate synthase inhibitors.
-
批准号:7608986
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2009
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Preclinical Development of Geranylgeranyl Disphosphate Synthase Inhibitors as Ant
-
批准号:7325831
-
项目类别:
-
资助金额:$12.31万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Developing Schweinfurthin Analogs as Glioma Therapies
-
批准号:8055678
-
项目类别:
-
资助金额:$11.25万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Novel Glioblastoma Therapeutics
-
批准号:7218415
-
项目类别:
-
资助金额:$10.99万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Developing Schweinfurthin Analogs as Glioma Therapies
-
批准号:7668303
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
海外基金